Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical Inc. (NASDAQ: ISRG), the pioneer of robotic-assisted minimally invasive surgery, provides critical updates through this comprehensive news hub. Track the latest developments surrounding the da Vinci Surgical System, regulatory milestones, and strategic initiatives shaping the future of surgical care.
This resource delivers verified press releases and financial updates essential for understanding ISRG's market position. Investors gain insights into earnings reports, partnership announcements, and technology advancements while medical professionals stay informed about clinical applications and procedural innovations.
Key content includes quarterly financial results, FDA clearances for new instruments, global expansion updates, and research collaborations advancing robotic surgery. All materials are sourced from official channels to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for real-time access to ISRG's evolving role in healthcare technology. Combine strategic awareness with operational knowledge through our curated collection of company-verified information.
A comprehensive meta-analysis published in Annals of Surgery has demonstrated significant benefits of da Vinci robotic surgery compared to laparoscopic and open surgical approaches. The study analyzed 230 studies from 22 countries over 12 years, including randomized controlled trials, prospective studies, and database reviews.
Key findings show that da Vinci robotic cases were 56% less likely to convert to open surgery versus laparoscopy, experienced 21% fewer blood transfusions versus laparoscopy and 75% versus open, and had 10% fewer 30-day postop complications versus laparoscopy and 44% versus open. Patients also experienced shorter hospital stays, though operative times were longer than both traditional approaches.
Intuitive (ISRG) reported strong financial results for Q3 2024. Key highlights include:
- Worldwide da Vinci procedures grew 18% year-over-year
- 379 da Vinci surgical systems placed, up from 312 in Q3 2023
- Installed base increased 15% to 9,539 systems
- Revenue rose 17% to $2.04 billion
- GAAP net income of $565 million ($1.56 per diluted share)
- Non-GAAP net income of $669 million ($1.84 per diluted share)
The company saw growth in da Vinci procedure volume and system placements. Instruments and accessories revenue increased 18%, while systems revenue grew significantly. Intuitive ended the quarter with $8.31 billion in cash and investments.
Jupiter Endovascular, a medical technology startup, has exited stealth mode with $21 million in new financing to fund a pivotal trial for Pulmonary Embolism. The company is developing a new class of endovascular procedures using Endoportal Control™ technology, which aims to bring the precision of direct surgical access to catheter-based interventions. Carl J. St. Bernard has been appointed as CEO, bringing over 30 years of experience in the life sciences industry.
The funding round, led by Sonder Capital with participation from strategic investors, will support the upcoming pivotal trial and development of additional clinical applications. Jupiter's technology addresses limitations in catheter-based therapies by providing stability and control within complex cardiovascular anatomies, potentially revolutionizing treatment for millions of patients worldwide.
Neptune Medical, a medical device innovator, has announced a successful $97 million Series D financing and the spinout of its subsidiary, Jupiter Endovascular. The financing round saw significant participation from Sonder Capital and Olympus of the Americas, along with other existing and new investors. This strategic move allows Neptune Medical to focus on gastrointestinal robotics, while Jupiter Endovascular will concentrate on its novel endovascular technology platform.
The financing will strengthen Neptune Medical's position in the GI space, as evidenced by the recent appointment of Dr. Fred Moll, a medical robotics pioneer, as Chairman of the Board. Both companies aim to lead innovation in their respective specialties, with Neptune pushing boundaries in GI robotics and Jupiter revolutionizing endovascular therapies.
Intuitive (NASDAQ:ISRG), a global leader in minimally invasive care and robotic-assisted surgery, has appointed its President David J. Rosa to the company's Board of Directors, effective July 24, 2024. Rosa joins CEO Gary S. Guthart as one of two Intuitive executives on the Board. With nearly 27 years at Intuitive, Rosa has held leadership positions across multiple functions and currently oversees the company's business unit, quality, regulatory, manufacturing, and commercial operations.
Rosa's appointment expands the Board from eleven to twelve directors, adding his deep operational experience to complement Guthart's focus on enterprise strategy. This move aims to balance strategy and operations at the Board level, enhancing Intuitive's stewardship.
Intuitive (Nasdaq: ISRG) reported strong Q2 2024 financial results, with revenue increasing 14% to $2.01 billion. Worldwide da Vinci procedures grew approximately 17% compared to Q2 2023. The company placed 341 da Vinci surgical systems, including 70 da Vinci 5 systems, bringing the total installed base to 9,203 systems, a 14% increase year-over-year.
GAAP net income attributable to Intuitive was $527 million, or $1.46 per diluted share, while non-GAAP net income was $641 million, or $1.78 per diluted share. Instruments and accessories revenue increased by 16% to $1.24 billion, driven by procedure volume growth. The company ended Q2 with $7.68 billion in cash, cash equivalents, and investments.
Intuitive (NASDAQ: ISRG) announced FDA clearance for revised labeling of its da Vinci X and Xi systems, specific to radical prostatectomy. The revision is based on real-world evidence from 2007 to 2014, indicating similar five- to 10-year cancer survival rates for robotic-assisted and open surgeries. This collaboration involved the FDA, Aetion, and NEST, highlighting the potential of real-world data in regulatory science. The labeling change reflects these findings, affirming the non-inferiority of robotic-assisted surgeries in cancer treatment outcomes.
FAQ
What is the current stock price of Intuitive Surgical (ISRG)?
What is the market cap of Intuitive Surgical (ISRG)?
